| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00562659 |
| P953 | full work available at URL | http://link.springer.com/content/pdf/10.1007/BF00562659.pdf |
| http://link.springer.com/article/10.1007/BF00562659/fulltext.html | ||
| http://link.springer.com/content/pdf/10.1007/BF00562659 | ||
| P698 | PubMed publication ID | 1233232 |
| P2093 | author name string | M. Eichelbaum | |
| L. Bertilsson | |||
| A. Rane | |||
| K. Ekbom | |||
| V. A. Ringberger | |||
| P2860 | cites work | Shortcomings in Pharmacokinetic Analysis by Conceiving the Body to Exhibit Properties of a Single Compartment | Q56166237 |
| Blood Levels of Drug at the Equilibrium State after Multiple Dosing | Q59056466 | ||
| Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography | Q66913495 | ||
| Carbamazepine for epilepsy. A controlled prospective evaluation | Q67288336 | ||
| Distribution and elimination kinetics of carbamazepine in man | Q67396517 | ||
| Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy | Q67826136 | ||
| Concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy | Q69038607 | ||
| Quantitative determination of carbamazepine in plasma by mass fragmentography | Q69304659 | ||
| Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy | Q69646920 | ||
| A micromethod for the determination of carbamazepine in blood by high speed liquid chromatography | Q69718675 | ||
| Carbamazepine in the Treatment of Tabetic Lightning Pains | Q70343321 | ||
| Mass Spectrometric Characterization of Carbamazepine-10,11-epoxide,a Carbamazepine Metabolite Isolated from Human Urine | Q70420847 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| carbamazepin | Q410412 | ||
| P304 | page(s) | 337-341 | |
| P577 | publication date | 1975-06-01 | |
| 1975-06-13 | |||
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses | |
| P478 | volume | 8 |
| Q52222033 | A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. |
| Q28327950 | A comparison of the efficacy and tolerability of controlled-release carbamazepine with conventional carbamazepine |
| Q34397398 | A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects |
| Q40142216 | Anticonvulsant drugs. An update |
| Q34270748 | Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics |
| Q40796225 | Antiepileptic medication interactions. |
| Q40265358 | Antiepileptic therapeutic drug monitoring. |
| Q40267429 | Application of stable labelled drugs in clinical pharmacokinetic investigations |
| Q36603317 | Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy |
| Q40962396 | Bioavailability of Four Different Pharmaceutical Preparations of Carbamazepine |
| Q36364659 | Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy |
| Q48146588 | Brain concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients |
| Q67549281 | Carbamazepine and its 10,11-epoxide in children and adults with epilepsy |
| Q46338118 | Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication |
| Q34987488 | Carbamazepine dose-frequency requirement in children |
| Q41112491 | Carbamazepine intoxication caused by interaction with isoniazid. |
| Q70058771 | Carbamazepine metabolism in man. Induction and pharmacogenetic aspects |
| Q40895629 | Carbamazepine overdose. Features of 33 cases |
| Q36706570 | Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism |
| Q38627226 | Carbamazepine toxicity and poisoning. Incidence, clinical features and management |
| Q34156256 | Characterization of the time course of carbamazepine deinduction by an enzyme turnover model |
| Q40877361 | Clinical Pharmacokinetics of Carbamazepine |
| Q39738819 | Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update |
| Q68249146 | Clinical pharmacokinetics in infants and children |
| Q34403438 | Clinically significant pharmacokinetic drug interactions with carbamazepine. An update |
| Q67029707 | Comparative bioavailability of two commercial preparations of carbamazepine tablets |
| Q50153894 | Comparison of the pharmacokinetics of diazepam after single and subchronic doses |
| Q62782509 | Computer analysis of saccadic eye movements: assessment of two different carbamazepine formulations |
| Q35078847 | Diseases Affecting Bone Quality: Beyond Osteoporosis |
| Q44487652 | Disposition of placentally transferred carbamazepine (Tegretol�) in the newborn |
| Q40828077 | Disposition of valproic acid in man |
| Q34345745 | Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients |
| Q38914642 | Drug level monitoring in paediatric practice |
| Q72589317 | Early stage autoinduction of carbamazepine metabolism in humans |
| Q43989983 | Effect of denzimol on carbamazepine and carbamazepine-10,11-epoxide concentrations in serum, liver, spleen and different brain regions of the rat: an inhibitory metabolic interaction |
| Q71763110 | Effect of dosage frequency of carbamazepine on drug serum levels in epileptic patients |
| Q70188687 | Effect of vitamin D2and D3on bone-mineral content in carbamazepine-treated epileptic patients |
| Q37322108 | Effects of antiepileptic drugs on hippocampal neurons coupled to micro-electrode arrays |
| Q42531502 | Effects of cimetidine on carbamazepine auto- and hetero-induction in man. |
| Q41789144 | Encephalopathy and Brain Stem Dysfunction in an Infant With Non-Accidental Carbamazepine Intoxication |
| Q46564322 | Enhanced clearance of carbamazepine using albumin-containing dialysate during CVVHDF. |
| Q60586286 | Epileptic patients refractory to drug therapy |
| Q42699921 | Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine |
| Q24811056 | Incorporating children's toxicokinetics into a risk framework |
| Q35827686 | Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants |
| Q41917893 | Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects |
| Q72577574 | Long-term observation of the relation between pain intensity and serum carbamazepine concentration in elderly patients with trigeminal neuralgia |
| Q41149339 | Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring |
| Q39661008 | Pharmacokinetic Description of Drug Interactions by Enzyme Induction: Carbamazepine-Clonazepam in Monkeys |
| Q67445131 | Pharmacokinetic Model to Describe Self‐Induced Decreases in Steady‐State Concentrations of Carbamazepine |
| Q39074126 | Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children |
| Q35759107 | Pharmacokinetics of drugs in overdose |
| Q34622792 | Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects |
| Q28329448 | Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure |
| Q40640453 | Plasma level monitoring of anticonvulsants |
| Q67826136 | Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy |
| Q36430811 | Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation |
| Q40083637 | Psychopharmacological aspects of antiepileptic treatment |
| Q36446899 | Safety and tolerability of mood-stabilising anticonvulsants in the elderly |
| Q43241380 | Saliva carbamazepine levels in children before and during multiple dosing |
| Q34448908 | Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients |
| Q45105829 | Serum Concentration of Carbamazepine: Comparison of Herrmann's Spectrophotometric Method and a New GLC Method for the Determination of Carbamazepine |
| Q44929720 | Simulated fluctuations in plasma drug concentrations for patients receiving oxcarbazepine or carbamazepine extended-release capsules |
| Q44640235 | Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules |
| Q71242227 | Simultaneous liquid chromatographic analysis for carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva by use of double internal standardization |
| Q69395064 | Simultaneous quantitation of salivary carbamazepine, carbamazepine-10,11-epoxide, phenytoin and phenobarbitone by high-performance liquid chromatography |
| Q66997369 | Simultaneous, rapid high-performance liquid chromatographic microanalysis of plasma carbamazepine and its 10,11-epoxide metabolite: applications to pharmacokinetic studies in humans |
| Q33683890 | Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex |
| Q44584927 | The Pharmacokinetics of Carbamazepine in Plasma and Saliva of Man |
| Q71049227 | The formation of carbamazepine epoxide by rat liver microsomes: an investigation of the biphasic kinetic profile |
| Q67052582 | The pharmacokinetics of carbamazepine |
| Q35174228 | The use of gabapentin for the treatment of postherpetic neuralgia |
| Q41690929 | Time course of carbamazepine self-induction |
| Q71634302 | Use of stable labelled carbamazepine to study its kinetics during chronic carbamazepine treatment |
Search more.